Type 2 diabetes is a persistent metabolic disorder characterized by elevated blood sugar levels attributed to insulin resistance and insufficient insulin production. The development of Type 2 diabetes is the result of a combination of genetic, lifestyle, and environmental factors. Effective management of type 2 diabetes can be achieved through dietary modifications, pharmaceutical interventions that aid in weight reduction, adherence to a healthy diet, and consistent physical activity.
In the realm of type 2 diabetes management, various classes of drugs are available, including dipeptidyl peptide-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas, other insulin secretagogues, biguanides, sodium-glucose cotransporter 2 inhibitors, and others. Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a class of oral medications designed to impede the action of the enzyme responsible for breaking down incretin hormones, which play a crucial role in regulating blood sugar levels. These drugs find applications in diverse areas, including glycemic control, cardiovascular safety, prevention of hypoglycemia, and more, catering to various age groups, including children and adults.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The type 2 diabetes market research report is one of a series of new reports from The Business Research Company that provides type 2 diabetes market statistics, including type 2 diabetes industry global market size, regional shares, competitors with a type 2 diabetes market share, detailed type 2 diabetes market segments, market trends and opportunities and any further data you may need to thrive in the type 2 diabetes industry. This type 2 diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The type 2 diabetes market size has grown strongly in recent years. It will grow from $48.14 billion in 2024 to $51.47 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to lifestyle and dietary changes, aging population, pharmaceutical developments, public health initiatives.
The type 2 diabetes market size is expected to see strong growth in the next few years. It will grow to $71.31 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to global diabetes epidemic, personalized medicine, technological advancements, healthcare policy changes. Major trends in the forecast period include digital health and telemedicine, prevention and early intervention, artificial intelligence (AI) and machine learning (ML), metabolic surgery.
The forecast of 8.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to GLP-1 receptor agonist autoinjectors imported from Denmark and France, potentially reducing medication adherence and increasing chronic care management burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of obesity and heart disease is expected to drive the growth of the type 2 diabetes market in the coming years. Obesity is a condition characterized by excessive body fat accumulation, while heart disease encompasses a variety of conditions affecting the heart and blood vessels. Excess weight increases the risk of insulin resistance, leading to elevated blood sugar levels and the development of type 2 diabetes. Conversely, high blood sugar can damage blood vessels and nerves, contributing to heart disease. For instance, in March 2024, the World Health Organization (WHO) reported that approximately one in eight people globally are affected by obesity. This includes 2.5 billion adults (aged 18 and older) who are overweight, with 890 million living with obesity. Among adults, 43% are overweight and 16% are obese. Additionally, 37 million children under five years old are overweight. As such, the rising rates of obesity and heart disease are fueling the growth of the type 2 diabetes market.
The rising geriatric population is expected to significantly propel the growth of the type 2 diabetes market in the coming years. The geriatric population, defined as individuals aged 65 years and older, is particularly vulnerable to various health issues due to reduced immunity and age-related factors. As people age, they are at increased risk for Type 2 diabetes-related complications such as hypoglycemia (low blood sugar), renal failure, and cardiovascular diseases, all of which can lead to both acute and chronic microvascular and cardiovascular problems. For example, in July 2023, the World Health Organization (WHO) projected that by 2030, 1 in 6 people worldwide will be aged 60 or older. Additionally, the global population of individuals aged 60 and above is expected to double to 2.1 billion by 2050, with a significant increase in the number of people aged 80 or older. Given these trends, the growing geriatric population is driving the demand for treatments and management solutions in the type 2 diabetes market.
Prominent companies operating in the type 2 diabetes market are pioneering innovative products such as Mounjaro to elevate the standards of safety and effectiveness in diabetic patient care. Innovative medications like Mounjaro aim to enhance the efficiency, safety, or convenience of diabetes management when compared to existing drugs. Advancements in the development of diabetes treatments focus on optimizing blood sugar regulation, minimizing adverse effects, and addressing other associated health issues. For instance, in May 2022, Eli Lilly and Co., a US-based pharmaceutical firm, secured approval from the U.S. Food and Drug Administration, a US-based government body, for Mounjaro (tripeptide) injection as an adjunct to diet and exercise for improving blood sugar control in adults with type 2 diabetes. Tirzepatide, a novel, dual-targeted therapy for type 2 diabetes, is delivered as a once-weekly injection, simultaneously targeting two hormones involved in blood sugar regulation, namely glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 contributes to increased insulin production and reduced glucagon production, while GIP stimulates insulin production. Tirzepatide stands as a promising novel treatment option for individuals with type 2 diabetes, including those who have responded poorly to other treatments.
In January 2024, Roche Group, a Switzerland-based healthcare company, acquired Carmot Therapeutics for an undisclosed amount. This acquisition allows Roche to gain access to Carmot's current R&D portfolio, including both clinical and pre-clinical assets, as well as exclusive rights to Carmot's innovative Chemotype Evolution discovery platform. This platform, which focuses on metabolism, will significantly enhance Roche's research and development capabilities in the fields of cardiovascular and metabolic diseases. Carmot Therapeutics, a clinical-stage biotechnology company, specializes in advancing therapeutics aimed at treating obesity and diabetes, and the acquisition aligns with Roche's strategy to expand its portfolio in metabolic disease treatments.
Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.
North America was the largest region in the type 2 diabetes market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the type 2 diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The type 2 diabetes market consists of revenues earned by entities by providing services such as blood sugar monitoring, diabetes education and support, bariatric surgery and lifestyle modifications. The market value includes the value of related goods sold by the service provider or included within the service offering. The type 2 diabetes market also includes sales of blood glucose meters, insulin pens, insulin syringes, insulin pumps, metformin and diabetic socks. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Type 2 Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on type 2 diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for type 2 diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The type 2 diabetes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists; Thiazolidinediones; Alpha-Glucosidase Inhibitors; Sulfonylureas And Other Insulin Secretagogues; Biguanides; SodiumGlucose Cotransporter 2 Inhibitors; Other Drug Classes
- 2) By Application: Glycemic Control; Cardiovascular Safety; Hypoglycemia Avoidance; Other Applications
- 3) By End-User: Children; Adults
- Subsegments:
- 1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
- 2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide; Semaglutide; Dulaglutide; Exenatide
- 3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
- 4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
- 5) By Sulfonylureas And Other Insulin Secretagogues: Glimepiride; Glipizide; Glyburide
- 6) By Biguanides: Metformin
- 7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
- 8) By Other Drug Classes: Amylin Analogues; Bile Acid Sequestrants; Dopamine Agonists
- Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc; Novartis AG; AstraZeneca plc; Abbott Laboratories; Sanofi SA; Medtronic plc; Takeda Pharmaceutical Company; GlaxoSmithKline plc.; Eli Lilly and Company; Novo Nordisk A/S; Johnson And Johnson Private Limited; Daiichi Sankyo Co. Ltd; Boehringer Ingelheim International GmbH; Dexcom Inc; Amgen Inc.; Insulet Corporation; Ascensia Diabetes Care; Byram Healthcare; Beta Bionics; Onduo LLC; DarioHealth; One Drop; Bigfoot Biomedical Inc.; Digbi Health; MySugr GmbH; Senseonics Holdings Inc.; Provention Bio Inc.; Vida Health Inc.; Diathrive Health
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Type 2 Diabetes Market Characteristics
3. Type 2 Diabetes Market Trends And Strategies
4. Type 2 Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Type 2 Diabetes Growth Analysis And Strategic Analysis Framework
- 5.1. Global Type 2 Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Type 2 Diabetes Market Growth Rate Analysis
- 5.4. Global Type 2 Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Type 2 Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Type 2 Diabetes Total Addressable Market (TAM)
6. Type 2 Diabetes Market Segmentation
- 6.1. Global Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- Thiazolidinediones
- Alpha-Glucosidase Inhibitors
- Sulfonylureas And Other Insulin Secretagogues
- Biguanides
- SodiumGlucose Cotransporter 2 Inhibitors
- Other Drug Classes
- 6.2. Global Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glycemic Control
- Cardiovascular Safety
- Hypoglycemia Avoidance
- Other Applications
- 6.3. Global Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Children
- Adults
- 6.4. Global Type 2 Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sitagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- 6.5. Global Type 2 Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Liraglutide
- Semaglutide
- Dulaglutide
- Exenatide
- 6.6. Global Type 2 Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pioglitazone
- Rosiglitazone
- 6.7. Global Type 2 Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acarbose
- Miglitol
- 6.8. Global Type 2 Diabetes Market, Sub-Segmentation Of Sulfonylureas And Other Insulin Secretagogues, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Glimepiride
- Glipizide
- Glyburide
- 6.9. Global Type 2 Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Metformin
- 6.10. Global Type 2 Diabetes Market, Sub-Segmentation Of Sodium-Glucose Cotransporter 2 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Canagliflozin
- Dapagliflozin
- Empagliflozin
- 6.11. Global Type 2 Diabetes Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Amylin Analogues
- Bile Acid Sequestrants
- Dopamine Agonists
7. Type 2 Diabetes Market Regional And Country Analysis
- 7.1. Global Type 2 Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Type 2 Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Type 2 Diabetes Market
- 8.1. Asia-Pacific Type 2 Diabetes Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Type 2 Diabetes Market
- 9.1. China Type 2 Diabetes Market Overview
- 9.2. China Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Type 2 Diabetes Market
- 10.1. India Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Type 2 Diabetes Market
- 11.1. Japan Type 2 Diabetes Market Overview
- 11.2. Japan Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Type 2 Diabetes Market
- 12.1. Australia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Type 2 Diabetes Market
- 13.1. Indonesia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Type 2 Diabetes Market
- 14.1. South Korea Type 2 Diabetes Market Overview
- 14.2. South Korea Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Type 2 Diabetes Market
- 15.1. Western Europe Type 2 Diabetes Market Overview
- 15.2. Western Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Type 2 Diabetes Market
- 16.1. UK Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Type 2 Diabetes Market
- 17.1. Germany Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Type 2 Diabetes Market
- 18.1. France Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Type 2 Diabetes Market
- 19.1. Italy Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Type 2 Diabetes Market
- 20.1. Spain Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Type 2 Diabetes Market
- 21.1. Eastern Europe Type 2 Diabetes Market Overview
- 21.2. Eastern Europe Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Type 2 Diabetes Market
- 22.1. Russia Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Type 2 Diabetes Market
- 23.1. North America Type 2 Diabetes Market Overview
- 23.2. North America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Type 2 Diabetes Market
- 24.1. USA Type 2 Diabetes Market Overview
- 24.2. USA Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Type 2 Diabetes Market
- 25.1. Canada Type 2 Diabetes Market Overview
- 25.2. Canada Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Type 2 Diabetes Market
- 26.1. South America Type 2 Diabetes Market Overview
- 26.2. South America Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Type 2 Diabetes Market
- 27.1. Brazil Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Type 2 Diabetes Market
- 28.1. Middle East Type 2 Diabetes Market Overview
- 28.2. Middle East Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Type 2 Diabetes Market
- 29.1. Africa Type 2 Diabetes Market Overview
- 29.2. Africa Type 2 Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Type 2 Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Type 2 Diabetes Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Type 2 Diabetes Market Competitive Landscape And Company Profiles
- 30.1. Type 2 Diabetes Market Competitive Landscape
- 30.2. Type 2 Diabetes Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck and Co. Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
31. Type 2 Diabetes Market Other Major And Innovative Companies
- 31.1. Sanofi SA
- 31.2. Medtronic plc
- 31.3. Takeda Pharmaceutical Company
- 31.4. GlaxoSmithKline plc.
- 31.5. Eli Lilly and Company
- 31.6. Novo Nordisk A/S
- 31.7. Johnson And Johnson Private Limited
- 31.8. Daiichi Sankyo Co. Ltd
- 31.9. Boehringer Ingelheim International GmbH
- 31.10. Dexcom Inc
- 31.11. Amgen Inc.
- 31.12. Insulet Corporation
- 31.13. Ascensia Diabetes Care
- 31.14. Byram Healthcare
- 31.15. Beta Bionics
32. Global Type 2 Diabetes Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Type 2 Diabetes Market
34. Recent Developments In The Type 2 Diabetes Market
35. Type 2 Diabetes Market High Potential Countries, Segments and Strategies
- 35.1 Type 2 Diabetes Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Type 2 Diabetes Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Type 2 Diabetes Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
